Table 2.
Comparison of published IC50 or effective doses with optimized concentrations determined from dose optimization studies for select inhibitors.
| Inhibitor | Optimal Concentration | Published IC50 / Effective Concentration (Target) [Reference] |
|---|---|---|
| RSC-133 | 50 μM | Effective dose: 10 μM (HDAC/DNMT) [34] |
| Tenovin-1 (Ref. values based on Tenovin-6) | 1 μM | 21, 10, 67 μM (SIRT1/2/3) [59] |
| CPTH2 | 5 μM | Effective dose of 50 [41, 60], 800 μM [60] (Gcn5) |
| SB939 | 0.25–0.5 μM | 77 nM (HDAC1) [32] |
| CAY10603 | 1 μM | 2 pM (HDAC6) [61] |
| OG-L002 | 20–80 μM | 0.2 μM (LSD1) [62] |